| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 | 446 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 297 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 | 149 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % | 26 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 3 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 | 123 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 | 30 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 | 9.19 |
Poly Medicure
Poly Medicure
1,951.00
+2.90
(0.15%)
Market Cap
19,739.30 Cr
EPS
34.13
PE Ratio
55.30
Dividend Yield
0.18 %
Industry
Healthcare52 Week High
3,357.80
52 Week Low
1,821.20
PB Ratio
7.15
Debt to Equity
0.08
Sector
Medical Equipment
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from5 analysts
Company News
View All News
Poly Medicure Limited acquired 100% of Citieffe Group, an Italian trauma and extremity orthopedic products manufacturer, for EUR 31 million enterprise value. The acquisition includes EUR 18.8 million equity valuation, EUR 4.2 million shareholder loan repayment, and EUR 8 million debt assumption. Citieffe, established in 1962 and based in Bologna, Italy, generated EUR 17.3 million revenue in 2024 with 15% growth and EUR 3.1 million EBITDA. The company operates at 60% capacity utilization with gross margins exceeding 90%. Citieffe has direct sales presence in Italy, US, and Mexico, holding 12% market share in Italy and Mexico. The acquisition provides Poly Medicure entry into the orthopedic space, specifically the $12 billion trauma and extremity segment growing at 6-7% annually. Key synergies include adding plates to Citieffe's product portfolio, US market expansion, potential manufacturing outsourcing to India, and leveraging Poly Medicure's distribution network. The existing management team, led by CEO Pascal Govi, will continue operations with performance-linked incentives over five years.
Poly Medicure Schedules Investor Call for September 25, 2025 on Citieffe Group Acquisition
7 days ago
7 days agoPoly Medicure Limited has announced an investor and analyst conference call scheduled for September 25, 2025 at 4:00 PM India time to discuss the proposed acquisition of Citieffe Group. The call will be represented by Managing Director Himanshu Baid and President of Strategy & Corporate Development Rahul Gautam. The company has provided dial-in details and registration links for participants to join the discussion.
Poly Medicure Acquires Italy's Citieffe Group for EUR 23 Million to Enter Global Orthopaedic Market7 days ago
7 days agoPoly Medicure Limited has acquired 100% of Citieffe Group, a vertically integrated trauma and extremity fixation systems company founded in 1962. The acquisition involves an equity valuation of EUR 18.8 million, with total upfront payout of EUR 23 million and enterprise value of EUR 31 million. Citieffe reported revenue of EUR 17.3 million and EBITDA of EUR 3.1 million for CY24, representing 15% and 14% year-on-year growth respectively. The company operates manufacturing facilities in Bologna, Italy, and has direct sales presence in Italy, USA, and Mexico, generating 85% of revenue from these markets. Citieffe holds 45 patents and maintains a 12% market share as the #2 independent player in Italy's trauma market. The transaction will be funded through cash balances and internal accruals, with closure expected within 4-8 weeks. Existing management, including CEO Pascal Govi, will continue post-acquisition. The deal provides Poly Medicure entry into the global orthopaedic market, particularly the trauma and extremities segment valued at USD 12 billion globally.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,951.00 | #1 19,739.30 | #6 55.30 | #1 1,759.00 | #6 22.62 | #1 339 | #2 25.81 | 44.32 | |
327.75 | 1,787.40 | 77.90 | 242.40 | 24.12 | 25 | -50.60 | 42.58 | |
309.00 | 1,623.60 | 59.59 | 408.40 | 32.64 | 30 | -55.00 | 29.32 | |
605.00 | 1,017.30 | 61.67 | 249.37 | 40.00 | 17 | -20.59 | 47.36 | |
596.00 | 957.90 | 47.95 | 186.60 | 40.62 | 20 | - | 53.31 | |
547.00 | 651.80 | 34.75 | 67.10 | 13.15 | 18 | 18.92 | 41.96 | |
274.95 | 518.80 | #1 32.50 | 136.30 | #1 107.77 | 16 | - | 60.73 | |
318.75 | 326.30 | 42.05 | 111.80 | -1.43 | 8 | -0.10 | 48.51 | |
287.00 | 304.80 | 37.71 | 89.85 | 0.60 | 7 | #1 752.54 | 55.44 | |
230.78 | 230.50 | - | 122.10 | 19.24 | 1 | -52.94 | 36.02 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
22.62 %
Net Income Growth
31.09 %
Cash Flow Change
-9.64 %
ROE
-30.34 %
ROCE
-30.22 %
EBITDA Margin (Avg.)
6.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 | 1,917 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 | 1,077 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 749 | 930 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 193 | 171 | 227 | 293 | 351 | 370 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 139 | 87 | 63 | 42 | 37 | 57 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 | 2,766 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 | -1,194 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 128 | 119 | 124 | 191 | 266 | 240 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % | 62.44 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % | 11.41 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % | 11.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % | 11.37 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % | 3.07 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 | 71,142 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 3.5 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
| 17 Sept 2021 |  Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,133.15 | 955.00 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 715.55 | 933.00 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 977.25 | 1,413.65 |
| 20 Sept 2024 | Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,654.70 | 2,462.65 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,498.45 | 2,318.00 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 2,450.95 | 2,514.10 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,445.25 | 2,433.90 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 2,587.85 | 2,584.60 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 2,057.40 | 1,931.65 |
| 18 Sept 2025 | Dividend | ₹ 3.50 /share | 18 Sept 2025 | 2,584.60 | 1,996.60 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 2,067.00 | 1,981.35 |
Announcements
Transcript Of Investors/Analysts Conference Call Held On 25Th September 2025.12 hours ago
12 hours agoShareholder Meeting / Postal Ballot-Scrutinizers Report4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
6 days agoClosure of Trading Window6 days ago
6 days agoShareholder Meeting / Postal Ballot-Outcome of AGM6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release (Revised)6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
7 days agoOutcome Of Board Meeting Held On Today I.E. 24Th September 2025 - Updates On Share Purchase Agreement For Acquisition Purpose Of "Citieffe Group"7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Updates on Acquisition8 days ago
8 days agoIntimation For Cancellation Investor/Analyst Meet Scheduled To Be Held On Today I.E. 19.09.2025Sep 19, 2025
Sep 19, 2025Intimation Of Investor/Analyst Call Scheduled To Be Held On Friday 19Th September 2025Sep 17, 2025
Sep 17, 2025Revised Intimation For The Investors/Analyst One To One Virtual Call Scheduled To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation Of Investor/Analyst One To One Virtual Meeting To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation For The Analyst/Investor Call As On 11Th September 2025.Sep 09, 2025
Sep 09, 2025Tranascript Of Investor/Analyst Conference Call Held On 04Th September 2025.Sep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesSep 05, 2025
Sep 05, 2025Book Closure For The Purpose Of Record Date For The Purpose Of DividendSep 05, 2025
Sep 05, 2025Record Date/Cut-Off Date For The Dividend PurposeSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Sep 04, 2025Intimation For Signing Of Share Purchase Agreement (SPA) Between Risor Holdings B.V. Amsterdam Netherlands A Wholly Owned Step-Down Subsidiary Of The Company With Wellinq Holdings B.V. Amsterdam Netherlands.Sep 04, 2025
Sep 04, 2025Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesSep 03, 2025
Sep 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 03, 2025
Sep 03, 2025Reg. 34 (1) Annual Report.Sep 03, 2025
Sep 03, 202530Th Annual General Meeting To Be Held On Thursday September 25 2025.Sep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 03, 2025
Sep 03, 2025Outcome Of Board Meeting_Acquisition(Incorporation Of A Wholly Owned Step Down Subsidiary "Risor Holdings B.V." In Amsterdam Netherlands And Updates On The Share Purchase Agreements (SPA)Sep 03, 2025
Sep 03, 2025Updates On Postponed And Rescheduled Investors/Analyst CallAug 28, 2025
Aug 28, 2025Investors/Analyst Call On Thursday 28Th August 2025Aug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Statement Of Deviation Or Variation In The Use Of Proceeds Of Equity Shares Issued Through QIP For The Quarter Ended June 30 2025 As Per Regulation 32 Of The SEBI (Listing Obligations & Disclosures Requirements) Regulations 2015Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 14, 2025
Aug 14, 2025Disclosure Of Analyst/ Investor Virtual Calls/Physical Meet On Multiple DatesAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 08, 2025
Aug 08, 2025Grant Of 3400 Stock Options Of Equity Shares Under ESOS 2020 Of The CompanyAug 08, 2025
Aug 08, 2025Re-Appointment Of Jai Prakash & Company Cost Accountants For The Financial Year 2025-26.Aug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Aug 08, 2025Unaudited Standalone & Consolidated Financial Results For The Quarter Ended 30Th June 2025 Declared As Outcome Of The Board Meeting Held On Today I.E. 08Th August 2025Aug 08, 2025
Aug 08, 2025Technical Indicators
RSI(14)
Neutral 44.32
ATR(14)
Less Volatile 64.07
STOCH(9,6)
Neutral 23.33
STOCH RSI(14)
Neutral 21.59
MACD(12,26)
Bearish -5.28
ADX(14)
Weak Trend 14.72
UO(9)
Bearish 43.29
ROC(12)
Downtrend And Accelerating -3.66
WillR(14)
Oversold -85.58
Mutual Fund Holdings
Invesco India Multicap Fund Direct-Growth 
SBI MNC Direct Plan-Growth 
Edelweiss Business Cycle Fund Direct-Growth 
Bank of India Small Cap Fund Direct-Growth 
WhiteOak Capital Flexi Cap Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
